Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 25
Filtrer
1.
JAMA Health Forum ; 5(8): e242755, 2024 Aug 02.
Article de Anglais | MEDLINE | ID: mdl-39212977

RÉSUMÉ

Importance: Nineteen states have passed legislation requiring insurers to cover the dispensation of a 12-month supply of short-acting, hormonal contraception. Objective: To determine whether 12-month contraceptive supply policies were associated with an increase in the receipt of 12-month or longer supply of contraception. Design, Setting, and Participants: This retrospective cohort study included data from all female Medicaid enrollees aged 18 to 44 years who used short-acting hormonal contraception (ie, pill, patch, or ring) from 2016 to 2020. Exposures: Eleven treatment states where legislation required insurers to cover a 12-month supply of contraception to continuing users and 25 comparison states without such legislation prior to December 2020. Main Outcomes and Measures: Proportion of contraception months received via a single 12-month or longer fill. Results: This study included 48 255 512 months of dispensed oral pill, patch, and ring contraception prescription supply among 4 778 264 female Medicaid enrollees. The majority of months of supplied contraception were for the contraceptive pill rather than the patch or ring. In a staggered difference-in-differences model, the 12-month supply policy was associated with an estimated 4.39-percentage point (pp) increase (95% CI, 4.38 pp-4.40 pp) in the proportion of contraception dispensed as part of a 12-month or longer supply, from a mean of 0.11% in treatment states during the first quarter of the study period. Investigating the heterogeneity in policy association across states, California stood out with a 7.17-pp increase (95% CI, 7.15 pp-7.19 pp) in the proportion of contraception dispensed as a 12-month or longer supply; in the other 10 treatment states, the policy association was less than 1 pp. Conclusions and Relevance: In this cohort study of Medicaid recipients using short-acting hormonal contraception, the passage of a 12-month contraceptive supply policy was associated with a minimal increase in the proportion of contraception dispensed through a 12-month or longer supply.


Sujet(s)
Medicaid (USA) , Humains , Medicaid (USA)/législation et jurisprudence , Medicaid (USA)/statistiques et données numériques , Femelle , États-Unis , Adulte , Études rétrospectives , Adolescent , Jeune adulte , Facteurs temps , Contraception/statistiques et données numériques , Contraception/méthodes , Politique de santé/législation et jurisprudence
2.
Contraception ; 138: 110512, 2024 Oct.
Article de Anglais | MEDLINE | ID: mdl-38852698

RÉSUMÉ

OBJECTIVES: This study aimed to determine the factors contributing to racial and ethnic disparities in the use of immediate postpartum, long-acting reversible contraception (IPP LARC) and permanent contraception among Medicaid recipients. STUDY DESIGN: We conducted a cross-sectional study using 3 years of national Medicaid claims data to examine the rates of IPP LARC use alone and a composite measure of postpartum permanent contraception and IPP LARC within 7 days of delivery by race and ethnicity. We used a Blinder-Oaxaca model to quantify the extent to which medical complexity, age, rurality, mode of delivery, and year explained differences in outcomes among different minoritized groups in comparison to non-Hispanic White women. RESULTS: Our study sample contained 1,729,663 deliveries occurring from 2016 through 2018 among 1,605,199 people living in 16 states. IPP LARC use rates were highest among Black (2.2%), followed by American Indian and Alaska Native at 2.1% and Hawaiian/Pacific Islander beneficiaries at 1.9%, Hispanic (all races) at 1.2%, and Asian at 1.0%. IPP LARC was lowest among White beneficiaries (0.8%). Medical complexity, age, rurality, year, and mode of delivery explained only 12.3% of the difference in IPP LARC rates between Black and White beneficiaries. Postpartum permanent contraception was highest among White (7.6%), Hispanic (7.2%), and American Indian and Alaska Native (6.8%), followed by Black (6.3%), Hawaiian/Pacific Islander (5.1%) and lowest among Asian women (4.1%). When we examined the use of IPP LARC or postpartum permanent contraception together, these same factors explained 94.4% of the differences between Black and White beneficiaries. CONCLUSIONS: While differences in the use of IPP LARC by race and ethnicity were identified, our findings suggest that overall use of inpatient highly effective contraception are similar across racial and ethnic groups. IMPLICATIONS: When IPP LARC and postpartum permanent contraception are examined jointly, their use is similar across racial and ethnic groups.


Sujet(s)
Ethnies , Contraception réversible à action prolongée , Medicaid (USA) , Période du postpartum , Humains , Femelle , États-Unis , Adulte , Contraception réversible à action prolongée/statistiques et données numériques , Études transversales , Jeune adulte , Medicaid (USA)/statistiques et données numériques , Adolescent , Ethnies/statistiques et données numériques , Contraception/statistiques et données numériques , Disparités d'accès aux soins/ethnologie , Disparités d'accès aux soins/statistiques et données numériques , Contraceptifs féminins/administration et posologie , Grossesse
3.
JAMA Health Forum ; 5(6): e241359, 2024 Jun 07.
Article de Anglais | MEDLINE | ID: mdl-38848089

RÉSUMÉ

Importance: Improving access to the choice of postpartum contraceptive methods is a national public health priority, and the need is particularly acute within the Medicaid population. One strategy to ensure individuals have access to the full range of contraceptive methods is the provision of a method prior to hospital discharge following a birth episode. Beginning in 2016, some states changed their Medicaid billing policy, allowing separate reimbursement for intrauterine devices and contraceptive implants to increase the provision of long-acting reversible contraceptive (LARC) methods immediately postpartum (IPP). Objective: To assess the association of a change in Medicaid billing policy with use of IPP LARC. Design, Setting, and Participants: The cohort study of postpartum Medicaid recipients in 9 treatment and 6 comparison states was conducted from January 2016 to October 2019. Data were analyzed from August 2023 to January 2024. Main Outcomes and Measures: The primary outcome was use of IPP LARC. Results: The final sample included 1 378 885 delivery encounters for 1 197 287 Medicaid enrollees occurring in 15 states. Mean age of beneficiaries at delivery was 27 years. The IPP LARC billing policy was associated with a mean increase of 0.74 percentage points (95% CI, 0.30-1.18 percentage points) in the immediate receipt of IPP LARC, with a prepolicy baseline rate of 0.54%. The IPP LARC billing policy was also associated with an overall increase of 1.48 percentage points (95% CI, 0.43-2.73 percentage points) in LARC use by 60 days post partum. Conclusions and Relevance: In this cohort study, changing Medicaid billing policy to allow for separate reimbursement of LARC devices from the global fee was associated with increased use of IPP LARC, suggesting that this may be a strategy to improve access to the full range of postpartum contraceptive methods.


Sujet(s)
Contraception réversible à action prolongée , Medicaid (USA) , Période du postpartum , Humains , Medicaid (USA)/législation et jurisprudence , Medicaid (USA)/statistiques et données numériques , Femelle , États-Unis , Contraception réversible à action prolongée/statistiques et données numériques , Contraception réversible à action prolongée/économie , Adulte , Études de cohortes , Politique de santé/législation et jurisprudence , Jeune adulte
5.
Biol Psychol ; 182: 108648, 2023 09.
Article de Anglais | MEDLINE | ID: mdl-37482132

RÉSUMÉ

An elevated P3a amplitude to trauma-related stimuli is strongly associated with posttraumatic stress disorder (PTSD), yet little is known about whether this response to trauma-related stimuli is affected by treatment that decreases PTSD symptoms. As an analysis of secondary outcome measures from a randomized controlled trial, we investigated the latency and amplitude changes of the P3a in responses in a three-condition oddball visual task that included trauma-related (combat scenes) and trauma-unrelated (threatening animals) distractors. Fifty-five U.S. veterans diagnosed with combat-related PTSD were randomized to receive either active or sham repetitive transcranial magnetic stimulation (rTMS). All received cognitive processing therapy, CPT+A, which requires a written account of the index trauma. They were tested before and 6 months after protocol completion. P3a amplitude and response time decreases were driven largely by the changes in the responses to the trauma-related stimuli, and this decrease correlated to the decrease in PTSD symptoms. The amplitude changes were greater in those who received rTMS + CPT than in those who received sham rTMS + CPT, suggesting that rTMS plays beneficial role in reducing arousal and threat bias, which may allow for more effective engagement in trauma-focused PTSD treatment.


Sujet(s)
Troubles psychiques liés à la guerre , Troubles de stress post-traumatique , Anciens combattants , Humains , Troubles psychiques liés à la guerre/psychologie , Troubles de stress post-traumatique/thérapie , Troubles de stress post-traumatique/psychologie , Stimulation magnétique transcrânienne/méthodes , Résultat thérapeutique , Anciens combattants/psychologie
6.
Contraception ; 126: 110116, 2023 10.
Article de Anglais | MEDLINE | ID: mdl-37453656

RÉSUMÉ

OBJECTIVE: We examine the association of the Hyde Amendment with obstetrical outcomes in a national Medicaid population. STUDY DESIGN: We conducted a national study of Medicaid-funded abortions to determine the association of restrictions on adolescent, preterm, low-birth weight, and short interpregnancy interval births using administrative data. RESULTS: States that restricted coverage for abortion had a higher median rate of adolescent (10.2%; vs 7.4%; p-value < 0.001), preterm (11.4%; vs 10.1%; p < 0.001), short interpregnancy interval, (13.0% vs 9.6%; p < 0.001), and low birth weight births (10.2% vs 8.7%; p = 0.003) than states where Medicaid provided comprehensive coverage. CONCLUSIONS: Restricting federal funds for abortion is associated with adverse outcomes. IMPLICATIONS: When Medicaid does not provide comprehensive coverage for abortion care, few abortions are provided and higher rates of adverse obstetrical outcomes are noted.


Sujet(s)
Avortement provoqué , Interruption légale de grossesse , Grossesse , Adolescent , Femelle , Nouveau-né , États-Unis , Humains , Medicaid (USA)
7.
Health Aff (Millwood) ; 42(4): 556-565, 2023 04.
Article de Anglais | MEDLINE | ID: mdl-37011308

RÉSUMÉ

Medicaid is characterized by low rates of provider participation, often attributed to reimbursement rates below those of commercial insurance or Medicare. Understanding the extent to which Medicaid reimbursement for mental health services varies across states may help illuminate one lever for increasing Medicaid participation among psychiatrists. We used publicly available Medicaid fee-for-service schedules from state Medicaid agency websites in 2022 to construct two indices for a common set of mental health services provided by psychiatrists: a Medicaid-to-Medicare index to benchmark each state's Medicaid reimbursement with that of Medicare for the same set of services, and a state-to-national Medicaid index comparing each state's Medicaid reimbursement with an enrollment-weighted national average. On average, Medicaid paid psychiatrists at 81.0 percent of Medicare rates, and a majority of states had a Medicaid-to-Medicare index that was less than 1.0 (median, 0.76). State-to-national Medicaid indices for psychiatrists' mental health services ranged from 0.46 (Pennsylvania) to 2.34 (Nebraska) but did not correlate with the supply of Medicaid-participating psychiatrists. As policy makers look to reimbursement rates as one strategy to address ongoing mental health workforce shortages, comparing Medicaid payment across states may help benchmark ongoing state and federal proposals.


Sujet(s)
Services de santé mentale , Psychiatrie , Sujet âgé , Humains , États-Unis , Medicaid (USA) , Medicare (USA) , Pennsylvanie
8.
Health Aff (Millwood) ; 42(4): 537-545, 2023 04.
Article de Anglais | MEDLINE | ID: mdl-37011322

RÉSUMÉ

Medicaid is the largest payer for publicly funded contraception, serving millions of women across the United States. However, relatively little is known about the extent to which effective contraceptive services vary geographically for Medicaid recipients. This study used national Medicaid claims to assess county-level variation in rates of provision of the most or moderately effective methods of contraception and provision of long-acting reversible contraception (LARC) across forty states and Washington, D.C., in 2018. County-level rates of most or moderately effective contraceptive use varied almost fourfold across states, from a low of 10.8 percent to a high of 44.4 percent. Rates of LARC provision varied almost tenfold, from a low of 1.0 percent to a high of 9.6 percent. Despite the fact that contraception is a core benefit within Medicaid, access and use vary substantially across and within states. Medicaid agencies have a variety of options to ensure that people have access to a choice of the full range of contraceptive methods, including removing or loosening utilization controls, incorporating quality metrics or value-based payments into contraceptive services, and adjusting reimbursement to remove barriers to the clinical provision of LARC.


Sujet(s)
Contraceptifs , Contraception réversible à action prolongée , États-Unis , Femelle , Humains , Medicaid (USA) , Contraception , Washington
10.
Health Aff (Millwood) ; 42(2): 172-181, 2023 02.
Article de Anglais | MEDLINE | ID: mdl-36745838

RÉSUMÉ

Despite Medicaid's importance as a payer and source of coverage for mental health care, relatively little is known about how prevalence, access, and quality might vary among Medicaid beneficiaries. This study used national Medicaid data from 2018 to assess regional variations in emergency department (ED) visits for mental health conditions, a measure that may reflect unmet needs for behavioral health care. We found substantial variations, with rates in the region with the highest visit rates eight times higher than those in the region with the lowest rates. Many regions with high rates of ED visits for mental health conditions also had high rates of outpatient mental health use. Regional patterns differed substantially, with some regions exhibiting high rates of ED visits related to anxiety but low rates for schizophrenia and vice versa. The presence of large variations in ED visits for mental health conditions, with substantial differences in the composition across regions, suggests a need for context-specific solutions, including assessments of the ways in which mental health benefits are structured at the state Medicaid agency level and of differences in provider accessibility and an understanding of the types of mental illness underlying high rates of use.


Sujet(s)
Medicaid (USA) , Troubles mentaux , États-Unis , Humains , Santé mentale , Troubles mentaux/épidémiologie , Troubles mentaux/thérapie , Troubles mentaux/psychologie , Service hospitalier d'urgences , Anxiété
11.
Contraception ; 122: 109959, 2023 06.
Article de Anglais | MEDLINE | ID: mdl-36708859

RÉSUMÉ

OBJECTIVES: To examine the association of Catholic hospitals with receipt of postpartum tubal ligation and long acting, reversible contraception among Medicaid recipients. STUDY DESIGN: We conducted a retrospective cohort study of live births from January 1, 2016 to October 31, 2016 to female Medicaid beneficiaries in the United States between ages 21 and 44. Our main exposure was the presence of a Catholic-affiliated sole community hospital, and our primary outcome was highly effective postpartum contraception. We examined rates of postpartum permanent contraception, along with the use of a long acting, reversible form of contraception (LARC) at 3 and 60 days are postpartum. We compared counties that had only a Catholic-affiliated hospital with counties with only a non-Catholic hospital. RESULTS: Our study population included 14,545 postpartum Medicaid beneficiaries. Study participants came from 88 counties across 10 United States states. Only 7.7% of women in counties with Catholic sole community hospitals received permanent contraception by 3 days postpartum, compared to 11.3% in counties with non-Catholic sole community hospitals (RD: -3.92%; 95% CI: -6.01%, -1.83%). This difference was not mitigated by receipt of outpatient procedures or long-acting, reversible contraception. Importantly, women residing in counties with Catholic sole community hospitals were much less likely to return postpartum for an outpatient visit between 8 and 60 days postpartum than women in counties with non-Catholic sole community hospitals (35.4% vs 45.4%, RD: -9.29%; 95% CI: -16.71%, -1.86%). CONCLUSIONS: In counties where the only hospital was Catholic, Medicaid recipients giving birth were significantly less likely to receive permanent contraception and to return for postpartum care. IMPLICATIONS: Catholic hospitals are increasing in the United States, which may restrict access to postpartum contraception, particularly in rural areas. We found that Medicaid recipients giving birth at a Catholic sole community hospital were less likely to receive permanent contraception and to return for care.


Sujet(s)
Hôpitaux communautaires , Medicaid (USA) , Grossesse , États-Unis , Femelle , Humains , Jeune adulte , Adulte , Études rétrospectives , Contraception , Période du postpartum
13.
Sarcoma ; 2020: 8363986, 2020.
Article de Anglais | MEDLINE | ID: mdl-32565716

RÉSUMÉ

Distinguishing well-differentiated liposarcoma (WDLPS) from dedifferentiated liposarcoma (DDLPS) is essential given distinct treatment paradigms and chemosensitivity. Percutaneous biopsy has a low sensitivity for detecting DDLPS. We sought to identify the diagnostic utility of positron emission tomography/computed tomography (PET/CT) in identifying WDLPS versus DDLPS. An independent radiologist reviewed PET/CT images to identify target lesions and determine the maximum standardized uptake value (SUVmax). An independent pathologist review confirmed WDLPS or DDLPS histology. A binary cutoff point of SUVmax was identified using a classification and regression trees (CART) algorithm. We identified 20 patients with WDLPS or DDLPS with 26 PET/CTs performed for separate recurrences that were followed by surgical sampling. Of the 26 records, 12 were DDLPS (46%) and 14 were WDLPS (54%). Patients with DDLPS had significantly higher SUVmax than those with WDLPS (p value = 0.0035). A SUVmax of 4 was identified as the cutoff point. Using this cutoff, the sensitivity of SUVmax identifying a case as DDLPS was 83.3% (95% CI: 51.6%, 97.9%) and the specificity was 85.7% (95% CI: 57.2%, 98.2%). PET/CT is a sensitive and specific diagnostic tool to identify the presence of dedifferentiation within the tumor.

14.
Pain ; 160(2): 298-306, 2019 Feb.
Article de Anglais | MEDLINE | ID: mdl-30673686

RÉSUMÉ

Social representation theory provides a framework for studying how scientific knowledge affects common sense and communication through inquiries into everyday discourse. This qualitative study examined social representations of chronic pain from 4 sources: North American newspapers; "Chronic Illness Cat" memes from the social media web site, Pinterest; video blogs on YouTube; and from a 2014 film, Cake, and interviews and comments concerning it. Using thematic analysis, we first identified social representations found in our 4 sources and others found in 1 or 2 of them. Second, we analyzed the sources for their rhetorical intentions. Vlogs directly and memes indirectly were first-person accounts, self-authorizing statements of the truth of chronic pain, whereas newspaper articles and the film were third-person accounts of pain, the differences between these perspectives affecting what was said. We conclude that the medium shapes the message.


Sujet(s)
Douleur chronique/épidémiologie , Douleur chronique/psychologie , Moyens de communication/statistiques et données numériques , Comportement social , Douleur chronique/étiologie , Humains
15.
J Surg Oncol ; 117(5): 879-885, 2018 Apr.
Article de Anglais | MEDLINE | ID: mdl-29448300

RÉSUMÉ

BACKGROUND: The role of surgical resection in the treatment of patients with metastatic/recurrent gastrointestinal stromal tumors (GIST) is unclear. The aim of this study was to identify preoperative factors associated with oncologic outcomes for recurrent/metastatic GIST after tyrosine kinase inhibitor (TKI) therapy. METHODS: We identified 107 patients with metastatic or recurrent GIST treated with TKIs and surgical resection (2002-2012). Patients that underwent palliative or incomplete resection were excluded. Complete resection was achieved in 87 patients which comprise the analytic cohort. Univariate and multivariate analyses were conducted to identify risk factors for GIST-specific survival (DSS) and time-to-recurrence (TTR). RESULTS: At a median follow-up of 51 months (91 months for survivors), median DSS was 74 months and TTR was 21 months. By univariate analysis, unifocal disease, duration of TKI < 365 days, and no evidence of radiographic progression were associated with improved TTR and DSS. Multivariate Cox regression demonstrated that evidence of radiographic progression was associated with shorter DSS (HR 2.53, 95%CI = 1.27-5.06, P = 0.008) and increased risk of recurrence (HR 3.33, 95%CI = 1.91-5.82, P < 0.001). CONCLUSIONS: Patients with unifocal disease and radiographic evidence of response to TKI therapy may achieve improved oncologic outcomes when complete surgical resection is achieved following treatment with TKI.


Sujet(s)
Tumeurs gastro-intestinales/anatomopathologie , Tumeurs stromales gastro-intestinales/secondaire , Traitement néoadjuvant , Récidive tumorale locale/anatomopathologie , Inhibiteurs de protéines kinases/usage thérapeutique , Adulte , Sujet âgé , Études de cohortes , Évolution de la maladie , Femelle , Études de suivi , Tumeurs gastro-intestinales/traitement médicamenteux , Tumeurs gastro-intestinales/chirurgie , Tumeurs stromales gastro-intestinales/traitement médicamenteux , Tumeurs stromales gastro-intestinales/chirurgie , Humains , Métastase lymphatique , Mâle , Adulte d'âge moyen , Récidive tumorale locale/traitement médicamenteux , Récidive tumorale locale/chirurgie , Soins préopératoires , Pronostic , Taux de survie , Observation (surveillance clinique) , Jeune adulte
16.
Cancer Biol Ther ; 18(10): 816-826, 2017 10 03.
Article de Anglais | MEDLINE | ID: mdl-29099264

RÉSUMÉ

Undifferentiated pleomorphic sarcomas (UPSs) are aggressive mesenchymal malignancies with no definitive cell of origin or specific recurrent genetic hallmarks. These tumors are largely chemoresistant; thus, identification of potential therapeutic targets is necessary to improve patient outcome. Previous studies demonstrated that high expression of activated protein kinase B (AKT) in patients with UPS corresponds to poor disease-specific survival. Here, we demonstrate that inhibiting phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) signaling using a small molecule inhibitor reduced UPS cell proliferation and motility and xenograft growth; however, increased phosphorylation of insulin-like growth factor 1 receptor (IGF1R) indicated the potential for adaptive resistance following treatment through compensatory receptor activation. Co-treatment with a dual PI3K/mTOR inhibitor and an anti-IGF1R kinase inhibitor reduced in vivo tumor growth rates despite a lack of antiproliferative effects in vitro. Moreover, this combination treatment significantly decreased UPS cell migration and invasion, which is linked to changes in p27 subcellular localization. Our results demonstrate that targeted inhibition of multiple components of the IGF1R/PI3K/mTOR pathway was more efficacious than single-agent therapy and suggest that co-targeting this pathway could be a beneficial therapeutic strategy for patients with UPS.


Sujet(s)
Antienzymes/pharmacologie , Inhibiteurs des phosphoinositide-3 kinases , Récepteurs des somatomédines/antagonistes et inhibiteurs , Sarcomes/traitement médicamenteux , Transduction du signal/effets des médicaments et des substances chimiques , Sérine-thréonine kinases TOR/antagonistes et inhibiteurs , Animaux , Lignée cellulaire tumorale , Mouvement cellulaire/effets des médicaments et des substances chimiques , Prolifération cellulaire/effets des médicaments et des substances chimiques , Inhibiteur p27 de kinase cycline-dépendante/métabolisme , Antienzymes/usage thérapeutique , Femelle , Humains , Imidazoles/pharmacologie , Imidazoles/usage thérapeutique , Souris , Souris hairless , Souris SCID , Thérapie moléculaire ciblée/méthodes , Phosphatidylinositol 3-kinase/métabolisme , Phosphorylation , Protéines proto-oncogènes c-akt/métabolisme , Pyrimidines/pharmacologie , Pyrimidines/usage thérapeutique , Pyrroles/pharmacologie , Pyrroles/usage thérapeutique , Quinoléines/pharmacologie , Quinoléines/usage thérapeutique , Récepteur IGF de type 1 , Récepteurs des somatomédines/métabolisme , Sarcomes/anatomopathologie , Sérine-thréonine kinases TOR/métabolisme , Tests d'activité antitumorale sur modèle de xénogreffe
17.
J Neurosurg ; 126(1): 319-329, 2017 Jan.
Article de Anglais | MEDLINE | ID: mdl-27035165

RÉSUMÉ

OBJECTIVE Malignant peripheral nerve sheath tumors (MPNSTs) are an aggressive group of soft tissue sarcomas that can arise sporadically, in the context of neurofibromatosis Type 1 (NF1) or at a site of prior irradiation. Large series profiling the features and outcomes of sporadic, NF1-associated, and radiation-associated MPNSTs are limited. The goal of this study was to elucidate differences between MPNST etiologies in a large single-institution retrospective study. METHODS Patients (n = 317) were identified through the tumor registry of The University of Texas MD Anderson Cancer Center. Clinicopathological features were retrospectively collected. Features were compared among MPNST subtypes for patients who had sufficient clinical history (n = 289), and clinicopathological features were used to identify adverse predictors of recurrence and survival outcomes. RESULTS Five-year local recurrence-free survival (LRFS), distant recurrence-free survival (DRFS), and disease-specific survival (DSS) estimates were 56.6%, 49.6%, and 53.6%, respectively, for the high-grade MPNST cohort. Five-year DSS was lower in NF1-associated and radiation-associated MPNST than in sporadic MPNST (52%, 47%, and 67%, respectively, p = 0.140). Patients with radiation-associated MPNST had worse 5-year LRFS than those with the sporadic and NF1-associated subtypes (RT-associated vs sporadic, p = 0.010; RT-associated vs NF1-associated, p = 0.232). Truncally located tumors, positive surgical margins, local recurrence, and metastasis were predictors of adverse DSS in multivariate analysis. CONCLUSIONS Radiation-associated MPNSTs are associated with poorer local recurrence-free and disease-specific survival than sporadic and NF1-associated tumors. NF1-associated MPNSTs may have worse survival outcomes owing to large tumor size, compromising truncal location, and lower rate of negative resection margins compared with sporadic tumors.


Sujet(s)
Récidive tumorale locale/épidémiologie , Tumeurs radio-induites/épidémiologie , Neurofibromatose de type 1/complications , Neurofibromatose de type 1/épidémiologie , Neurofibrosarcome/épidémiologie , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Enfant , Enfant d'âge préscolaire , Femelle , Études de suivi , Humains , Nourrisson , Mâle , Adulte d'âge moyen , Grading des tumeurs , Tumeurs radio-induites/anatomopathologie , Neurofibromatose de type 1/anatomopathologie , Neurofibromatose de type 1/thérapie , Neurofibrosarcome/étiologie , Neurofibrosarcome/anatomopathologie , Neurofibrosarcome/thérapie , Études rétrospectives , Analyse de survie , Jeune adulte
18.
Clin Exp Ophthalmol ; 45(5): 520-528, 2017 Jul.
Article de Anglais | MEDLINE | ID: mdl-28013525

RÉSUMÉ

BACKGROUND: Microinvasive glaucoma surgery (MIGS) is a relatively new addition to the glaucoma treatment paradigm. Small metallic stents are inserted into the trabecular meshwork in order to increase aqueous humour drainage. MIGS procedures are rapidly being adopted owing to a more favourable side effect profile when compared with traditional surgery. Remarkably, this rapid rate of utilization has occurred without any published studies on the effect of metal alloys used in these stents on human trabecular meshwork cells (HTMCs). Therefore, this study aimed to determine the effect of candidate metal alloys for MIGS on HTMC morphology, viability and function. METHODS: Human trabecular meshwork cells were cultured on the surfaces of titanium (polished and sandblasted), a titanium-nickel (nitinol) alloy and glass (as control substratum). Fluorescence imaging was used to assess cell morphology and spreading. A lactate dehydrogenase cytotoxicity assay, cell death detection ELISA, MTT cell viability assay, BrdU cell proliferation assay and fibronectin ELISA were also conducted. RESULTS: Cells cultured on sandblasted titanium exhibited significantly greater spreading than cells cultured on other substrata. In comparison, HTMCs cultured on nitinol displayed poor spreading. Significantly more cell death, by both necrosis and apoptosis, occurred on nitinol than on titanium and glass. Also, cell viability and proliferation were suppressed on nitinol compared with titanium or glass. Finally, HTMCs on both titanium and nitinol produced greater amounts of fibronectin than cells grown on glass. CONCLUSIONS: Substratum topography and metal alloy composition were found to impact morphology, viability and function of primary HTMC cultures.


Sujet(s)
Alliages/pharmacologie , Chirurgie filtrante/méthodes , Implants de drainage du glaucome , Glaucome/anatomopathologie , Interventions chirurgicales mini-invasives , Réseau trabéculaire de la sclère/ultrastructure , Apoptose , Prolifération cellulaire , Survie cellulaire , Cellules cultivées , Colorimétrie , Test ELISA , Glaucome/métabolisme , Glaucome/chirurgie , Humains , Microscopie électronique à balayage , Microscopie de fluorescence , Réseau trabéculaire de la sclère/effets des médicaments et des substances chimiques , Réseau trabéculaire de la sclère/métabolisme
19.
Ann Surg Oncol ; 23(Suppl 5): 962-967, 2016 12.
Article de Anglais | MEDLINE | ID: mdl-27646022

RÉSUMÉ

BACKGROUND: Brain metastasis from sarcoma is rare, thus limited information is available. We examined sarcoma brain metastases diagnosed at our institution over a period of 28 years. METHODS: This is a retrospective study of 112 cases. Clinical records were reviewed and clinical, pathological, and survival data were tabulated. RESULTS: Undifferentiated sarcoma was the most common source. In 50 % of cases, the primary sarcoma was in the extremities. Most patients were adults at the time of first brain metastasis, and median age was 34.8 years. Although most patients evidenced metastatic disease to other sites prior to developing brain metastasis, in almost one quarter, brain was the initial site. Most of the metastatic foci were parenchymal, nonhemorrhagic, and solitary. Forty percent of the brain metastatic deposits were located in the frontal lobes. Thirty-one percent recurred-all within 5.3 years. Seventy-six percent of patients succumbed to the disease, with a median survival time of only 0.6 years. Hemorrhagic metastatic foci were found to be associated with significantly lower recurrence-free, as well as disease-specific survivals. No difference in survival was noted between single versus multiple deposits or primary soft tissue versus bone sarcomas. No statistically significant effect on survival was found when neurosurgical resection was combined with radiotherapy. Chemotherapy, on the other hand, was found to significantly improve disease-specific survival when combined with metastasectomy. CONCLUSIONS: Undifferentiated sarcoma was the most common source of brain metastasis. Most cases showed evidence of prior metastatic disease. Surgical resection is employed to manage symptoms, but prognosis remains dismal.


Sujet(s)
Tumeurs osseuses/anatomopathologie , Tumeurs du cerveau/secondaire , Sarcomes/secondaire , Tumeurs des tissus mous/anatomopathologie , Adolescent , Adulte , Sujet âgé , Tumeurs du cerveau/complications , Tumeurs du cerveau/anatomopathologie , Tumeurs du cerveau/thérapie , Enfant , Enfant d'âge préscolaire , Survie sans rechute , Membres , Femelle , Lobe frontal , Humains , Nourrisson , Mâle , Adulte d'âge moyen , Études rétrospectives , Sarcomes/complications , Sarcomes/anatomopathologie , Sarcomes/thérapie , Taux de survie , Jeune adulte
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE